You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 08/28/2014

Company Name Symbol %Change
SIGNET JEWEL SIG
7.72%
CHYRONHEGO C CHYR
5.84%
INUVO INC INUV
4.76%
P L C SYSTEM PLCSF
4.48%
US SILICA HO SLCA
4.00%
Beststocksdaily.com Issues Investment Alert On (NYSE: STO), (NASDAQ: TELK), (NASDAQ: ONCY), (NYSE: BBY), (NYSE: CVS)

Print Share

Los Angeles, CA, Dec 13, 2012 (eTeligis.com via COMTEX) Statoil ASA(ADR)(NYSE:STO) stock fell 0.52% to $24.66. Standard & Poor's Ratings Services (S&P) announced credit ratings for Statoil ASA at AA-/A-1+ with stable outlook. The ratings reflect the Group's stand-alone credit profile, which S&P assesses at 'a+'. S&P assesses Statoil's business risk profile as "strong" and financial risk profile as "modest." The ratings include one notch of uplift to reflect extraordinary state support from the Kingdom of Norway, 67%-owner. The short-term rating is 'A-1+'.

Will STO Move Higher After Today's Sudden Selling Activities? Don't Miss The Free Trend Analysis here http://beststocksdaily.com/p2/index.php?company=STO

Telik, Inc.(NASDAQ:TELK) shares climbed 38.64% to $2.47 in the early hour. The company announced the publication of a clinical trial abstract in the proceedings of the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. The abstract, "Oral EzatiostatHCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN).

How Should Investors Trade TELK After The Recent Momentum, Find Out Here http://beststocksdaily.com/p2/index.php?company=TELK

Oncolytics Biotech, Inc. (USA)(NASDAQ:ONCY) shares soared 71.88% to $3.68 in the morning hour after the company announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-nave head and neck cancers (REO 018). The endpoint examines initial percentage tumour changes between the pre-treatment and first post-treatment scans (typically performed at six weeks post-first treatment) of all patients enrolled in the study.

Get Free Special Trend Analysis On ONCY Here http://beststocksdaily.com/p2/index.php?company=ONCY

Best Buy Co., Inc.(NYSE:BBY) stock gained 17.49% to $14.34. The company's founder Richard Schulze is expected to make a fully financed offer to buy the consumer electronics retailer by a mid-December deadline. Schulze's bid would be at least $5 billion to $6 billion.

Additionally, Bank of America announced that they have downgraded electronics retailer, Best Buy Co. The firm, which did not have a previous rating on the company, reported that they have downgraded BBY to a "Underperform," and have given the company a $9 price target.

Get Free Special Trend Analysis On BBY Here http://beststocksdaily.com/p2/index.php?company=BBY

CVS Caremark Corporation(NYSE:CVS) stock increased 3.60% to $49.26 after the company reaffirmed its guidance for the full-year 2012, and also boosted its quarterly dividend by about 38%.

The company said it continues to expect fiscal 2012 earnings in a range of $3.38 to $3.41 per share. Analysts expected the company to report earnings of $3.40 per share for fiscal 2012.

Additionally, the company said its board has approved an increase in its quarterly dividend of about 38% to $0.225 per share on the common stock of the company, payable on February 4 to holders of record on January 24, 2013.

Get Free Special Trend Analysis On CVS Here http://beststocksdaily.com/p2/index.php?company=CVS

About Beststocksdaily

Beststocksdaily's team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily's instant stock news on Major Gainers, Hot Stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Beststocksdaily.com.

Disclaimer:

The assembled information disseminated by beststocksdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. beststocksdaily.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.

CONTACT:

Brain Burr

Beststocksdaily

1419 Westwood Blvd Los Angeles, CA

90024-4911

staff@beststocksdaily.com

www.beststocksdaily.com

SOURCE BestStocksDaily.com

Associated Documentation:Link to submission on http://www.eteligis.comBestStocksDaily.com_12-13-2012_KMG_2.docx

Copyright eTeligis Inc. 2012. All rights reserved.

**********************************************************************

As of Sunday, 12-09-2012 23:59, the latest Comtex SmarTrendA? Alert,
an automated pattern recognition system, indicated a DOWNTREND on
03-29-2012 for BBY @ $24.72.

As of Sunday, 12-09-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated an UPTREND on
05-02-2012 for CVS @ $45.54.

As of Sunday, 12-09-2012 23:59, the latest Comtex SmarTrend Alert,
an automated pattern recognition system, indicated a DOWNTREND on
03-29-2012 for STO @ $26.61.

For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright A? 2004-2012 Comtex News Network, Inc. All rights reserved.

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.